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Abstract
Background. Hyperuricaemia is a well known side-
effect of cyclosporin A (CsA) treatment. The patho-
genic mechanisms, however, remain controversial.
There is no convincing evidence that hyperuricaemia
is due to CsA-induced, impaired tubular handling of
uric acid. The impact of diminished GFR in this
particular context has never been investigated.
Methods. We prospectively studied plasma uric acid,
inulin clearances, and fractional clearances of uric acid
in two groups of CsA-treated patients (bone-marrow
transplant patients, n = 50; renal transplant patients,
n = 32), and one healthy control group without CsA
(living related kidney donors, n = 28). Bone-marrow
transplant patients were examined before transplanta-
tion and 6, 12, 18, 24 months after transplantation,
renal transplant patients 1 year after transplantation,
and living related kidney donors before and 1 year
after unilateral nephrectomy.
Results. After 1 year of CsA treatment, hyperuricaemia
was found in 36% of bone-marrow transplant patients
and in 53% of renal transplant patients. Thirty per
cent of living related kidney donors were borderline
hyperuricaemic 1 year after unilateral nephrectomy.
The fractional clearance of uric acid, measured serially
in bone-marrow transplant patients did not change
significantly over time; it was, however, slightly higher
during CsA treatment than after CsA withdrawal.
Moreover, the bone-marrow transplant patients' frac-
tional clearance of uric acid was not statistically differ-
ent from the renal transplant patients' and the living
related kidney donors' (values 1 year after transplan-
tation/unilateral nephrectomy: bone-marrow trans-
plant patients, 15.3 + 2.3%; renal transplant patients,
11.9 ±0.9%; living related kidney donors, 11.1+0.8%).
The GFR at 1 year, measured by inulin clearance, was
identical in the CsA-treated groups and slightly higher
in the living related kidney donors (bone-marrow
transplant patients, 51±6ml/min per 1.73 m2; renal
transplant patients, 49 + 3ml/min per 1.73 m2; living
related kidney donors, 61 ±2 ml/min per 1.73 m2).
Conclusion. There is no evidence for impaired tubular
handling of uric acid, induced by a CsA-specific tubulo-
Correspondence and offprint requests to: Regula ZQrcher MD,
Clinique de Medecine n, Hopital Cantonal Universitaire, rue
Micheli-du-Crest 24, CH-1211 Geneve 14, Switzerland.
toxic effect. Hyperuricaemia in CsA-treated transplant
patients can therefore be attributed to the cyclosporin-
associated decrease of GFR.
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Introduction
CsA-associated hyperuricaemia was described for the
first time in 1983 [1]. Since then, several authors have
confirmed this finding and have speculated about its
pathogenesis, attributing hyperuricaemia to diminished
renal function, diuretic use, or impaired tubular hand-
ling of uric acid [2-16]. The hypothesis of decreased
fractional clearance of uric acid during CsA adminis-
tration has been tested in its relationship with creatin-
ine clearance [4,5] and, except in one small study [6],
has never been tested in relation to GFR itself, meas-
ured by classical inulin clearance. Diuretic use is a
confounding variable in most studies. Furthermore,
the fractional clearance of uric acid in CsA-treated
patients has always been compared to azathioprine-
treated patients and has never been formally compared
to a healthy control group with comparable renal
function but without immunosuppressive medication.
In order to define better the contribution of dimin-
ished GFR and tubular dysfunction respectively to
hyperuricaemia, we conducted a prospective study,
investigating inulin clearances and fractional clearances
of uric acid in CsA-treated patients without (bone-
marrow transplant patients) and with (renal transplant
patients) underlying renal disease, as well as in a
healthy control group without CsA and without kidney
disease (living related kidney donors).
Subjects and methods
Selection and treatment of patients
Two groups of CsA-treated patients and one control group
were studied: (a) a total of 50 consecutive patients who
received CsA for allogenic bone marrow transplantation at
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the haematological unit of our hospital between 1988 and
1991 (CsA-group without underlying renal disease), (b) 32
consecutive CsA-treated patients who received a renal allo-
graft from a living related kidney donor between 1988 and
1992 (group with underlying renal disease), and (c) 28 living
related kidney donors (control group without underlying
disease and without any immunosuppression) were entered
in the study after having given written informed consent.
Investigations were performed as follows: plasma uric acid,
inulin and creatinine clearances, and fractional clearance of
uric acid before and 6, 12, 18 and 24 months after bone-
marrow transplantation (regardless of whether or not CsA
was discontinued), 1 year after renal transplantation, and
before and 1 year after unilateral nephrectomy respectively.
Exclusion criteria: bone-marrow transplant patients who
could not be followed for up to at least 12 months (because
of death, relapse of leukaemia, severe infections, non-
compliance), were excluded from analysis (n = 23). Moreover,
single investigations were excluded when patients received
drugs that alter the synthesis or excretion of uric acid.
Concomitant drugs: maintenance immunosuppression con-
sisted of CsA alone or in combination with low-dose pred-
nisone in bone-marrow transplant patients (mean CsA
dose 280 mg/day) and of CsA monotherapy (n = 21),
CsA-azathioprine (n — 3), CsA-azathioprine-prednisone
(n = 7) and CsA-prednisone (n=l) in the renal transplant
group (mean CsA dose 300 mg). Diuretics were used by none
of the bone-marrow transplant patients after transplantation.
In the renal transplant group 21 of 32 patients received one
or several antihypertensive drugs, only five of them, however,
in combination with a diuretic (furosemide). None of the
living related kidney donors was on diuretic therapy. At
timepoint 0 of bone-marrow transplantation, most patients
were on a multidrug regimen, including antimicrobial and
antiviral drugs.
According to normal range values of the laboratory in our
hospital, hyperuricaemia was considered to be present when
the plasma uric acid level was above 490 umol/1 in men and
above 360 umol/1 in women.
Clearance techniques
GFR was measured by standard inulin-clearance techniques:
patients were admitted to our nephrology ward and well
hydrated on the eve of the examination day (1 litre of water
orally for all but the bone-marrow-transplant patients before
transplantation, who usually received 3 litres of i.v. saline in
glucose per 24 h). The patients also received their evening
meal and breakfast, each standardized in protein and salt
content. CsA as well as other drugs were withheld until the
end of the clearance period on the study day.
On the morning of the examination day, the patients were
further hydrated, first with i.v. glucose 5%, 5 ml/kg body
weight over 30 min. The infusion was then changed to inulin
in 0.9% saline. The dose of inulin was calculated to provide
an inulin blood concentration of 30mg/100ml. After the
loading dose was infused over 10-15 min, a maintenance
dose of inulin was delivered by a constant infusion pump.
Sixty minutes were allowed for equilibration. Then four
timed urine collections were obtained by spontaneous voiding
at 40-min intervals. After voiding, the patients drank 250 ml
of water to allow urine flow rates > 5 ml/min. Blood samples
were drawn midway into each collection period. Clearance
values for inulin, creatinine and fractional clearance of uric
acid were calculated for each period. The results given below
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are the mean ± SEM of the four clearance periods. All
clearance values are expressed per 1.73 m2 body surface area.
Laboratory methods
Uric acid concentrations in plasma and urine were measured
using a uncase method (Hitachi 737, Boehringer Mannheim),
plasma and urine creatinine concentrations by a creatinin-
ase assay (Wako Chemicals GmbH, Neuss; Hitachi 737,
Boehringer Mannheim). Inulin concentrations were measured
by perchlorate hydrolysis.
Statistical analysis
Statistical evaluation was performed using one-way ANOVA
for unpaired tests and paired t tests for paired analysis.
Correlations were evaluated using linear least squares regres-
sion; P<0.05 was considered significant and two-sided tests
were used throughout. Data are given as mean ± SEM.
Results
Plasma uric acid
Plasma uric acid levels of bone-marrow transplant
patients were comparable to those of renal transplant
patients under CsA (P NS; Table 1). Plasma uric acid
rose significantly during CsA therapy in bone-marrow
transplant patients (paired t test; « = 14; P<0.05) and
decreased to normal levels after CsA was stopped
(Figure 1). This phenomenon was similar in males and
females. Living related kidney donors experienced a
significant rise in plasma uric acid after nephrectomy
(paired t test; /)<0.001), 9 of 28 becoming borderline
hyperuricaemic.
Fractional clearance of uric acid and inulin
clearance
In bone-marrow transplant patients the fractional
clearance of uric acid remained stable over the whole
range of GFR examined, i.e. between an inulin clear-
ance of 106 (before bone-marrow transplantation) to
45 ml/min per 1.73 m2 (24 months after bone-marrow
transplantation), regardless of whether CsA was used
or not (Table 2a, b). There were no statistically signi-
ficant changes between values obtained before CsA
was introduced, those obtained under CsA therapy,
and those obtained after withdrawal of the drug. If
anything, there was a tendency towards higher values
during CsA therapy compared to those after discon-
tinuing it. The renal transplant patients receiving CsA
therapy had values for the fractional clearance of uric
acid and inulin clearances comparable to those of the
bone-marrow transplant patients (Table 2a, b). The
fractional clearance of uric acid of the living related
kidney donors was somewhat lower but not statistically
different from that of the two patient populations
under CsA (Table 2a).
Likewise, there were no differences in paired tests of
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BMTO
BMT 6m
BMT 12m
BMT 18m
BMT 24m
LRKDO
LRKDly
RTP ly
P-UA
n
9
7
6
3
13
? Gunol/1)
CsA +
366 ±30
411±53
367 ±23
409 ±44
404±24
n
8*
4
4
4
16
16
CsA-
232±19
271 ±21
255 ±39
259 ±46
290 ±16
323±16
P-UA
n
12
6
6
2
19
<J (umol/1)
CsA +
449±34
477 ±38
502 ±23
490 ±49
456 ±19
n
13*
10
6
14
12
12
C s A -
303 ±23
351 ±18
381 ±18
351 ±19
407 ±17
451 ±14
Data are given as mean±SEM.
BMT, Bone-marrow transplant patients (O=before; 6, 12, 18, 24 months after tx).
LRKD, Living related kidney donors (0 = before, ly = l year after unilateral nx).
RTP, Renal transplant patients (ly = 1 year after tx).
* Patients on allopurinol excluded.
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Fig. 1. Plasma uric acid (P-UA), fractional clearance of uric acid (fCUA) and GFR over time in bone-marrow transplant patients on and
off CsA (see details in Tables 1, 2a, 2b).
the bone-marrow transplant patients (same patient
before transplantation and after 6 months on CsA;
n = l l ) and the living related kidney donors/renal
transplant patients ('sibling' kidney with and without
CsA; n = 23): fractional clearance of uric acid
before bone-marrow transplantation 13.0%±1.6 vs
13.3%±0.9 on CsA; fractional clearance of uric acid
10.9%±0.8 in living related kidney donors 1 year after
nephrectomy and 10.3+0.7% in renal transplant
patients 1 year after transplantation.
Discussion
Hyperuricaemia has been described as a complication
of CsA therapy in 30-84% of patients, depending on
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Table 2a. Fractional clearance of uric acid (fCUA)
BMTO
BMT6m
BMT 12m
BMT 18m
BMT 24m
LRKDO
LRKD ly
RTP ly
fCUA
n
21
13
11
7
32
CsAyes
12.7 ±0.8°"
15.3 ±2.3°"
13.2 ±1.6°"
14.111.70'1
11.9 ±0.9°"
n
27
13
11
16
28
28
CsA no
14.3 +1.20'1'2
12.8 ±1.2°
11.7±0.5°
12.8±0.8°
10.7 ± O.I"2
H.l±0.81/3
Data are given as mean±SEM.
BMT, Bone-marrow transplant patients,
0 = before, 6, 12, 18, 24 months after transplantation.
LRKD, Living related kidney donors,
0 = before, l y = l year after unilateral nephrectomy.
RTP Renal transplant patients, l y = 1 year after transplantation.
°BMT CsA no vs BMT CsA yes/RTP CyA yes, P NS.
'BMT CsA yes/RTP CsA yes vs LRKD 0/ly, P NS.
2BMT 0 vs LRKD 0, P<0.05.
3BMT 0 vs LRKD ly, /><0.05.
Table 2b. Inulin clearance/1.73 m2 (CIN 1.73)
BMTO
BMT 6m
BMT 12m
BMT 18m
BMT 24m
LRKDO
LRKD ly
RTP ly
CIN ]
n
21
13
11
7
32
1.73
CsA yes
57
 ±4o/3
5 1 ± 6 O/W3
5 6 ± 70/1/3
45 ± 70/1/3
49
 ± 32/3
n
27
13
11
16
28
28
CsA no
106±6°
79 ±7'
83±3'
79 ±5'
97±4
61 ±22
Data are given as mean±SEM.
BMT, Bone-marrow transplant patients,
0 = before, 6, 12, 18, 24 months after transplantation.
LRKD, Living related kidney donors,
0 = before, 1 y = 1 year after unilateral nephrectomy.
RTP, Renal transplant patients, ly= 1 year after transplantation.
°BMT 0 vs BMT 6m/12m/18m/24m CsA yes, P<0.001.
JBMT 12m/18m/24m CsA yes vs BMT 12m/18m/24m CsA no,
2 LRKD ly vs BMT 12 m CsA yes/RTP ly CsA yes, P<0.05.
3BMT 6m/12m/18m/24m CsA yes vs RTP CsA yes, P NS.
how hyperuricaemia is defined [2-4, 9-15]; clinical
gout has been reported in 4—24% of all CsA-treated
patients, whereas it is hardly ever noticed in patients
under azathioprine [2,4,13-16]. Several authors have
speculated about the pathogenesis of this phenomenon.
All of them agree that an important cause is the
decrease of renal function in CsA-treated patients.
Another important factor is the use of diuretics
[2,4,16]. The turnover rate of uric acid, however, was
shown to be not different in CsA-treated patients and
in patients receiving azathioprine [2]. Some authors
suggest that there is reversible [5,8,16] or irreversible
[4] tubular damage, leading to impaired tubular hand-
ling of uric acid and resulting in lower fractional
R. M. Zurcherera/
clearance of uric acid in CsA-treated patients than in
patients under azathioprine.
Our study with serial measurements in bone-marrow
transplant patients confirms the existence of hyper-
uricaemia under CsA as well as its reversibility when
CsA is withdrawn and GFR is restored (Table 1/
Figure 1). At 6 months there was a good correlation
between plasma uric acid and plasma creatinine (r =
0.75; P<0.001).
If hyperuricaemia in CsA treated patients were due
to tubular dysfunction, resulting in diminished net
secretion of uric acid, the fractional clearance of uric
acid would be expected to decrease. Serially measured
values of the fractional clearance of uric acid of bone-
marrow transplant patients, however, did not change
significantly over time, regardless of whether patients
were on or off CsA (Table 2a/Figure 1). If anything,
there was a tendency towards higher values during
CsA therapy compared to those after discontinuing it.
When intraindividual changes in the fractional clear-
ance of uric acid with vs without CsA were analysed,
there were no statistical differences either.
Since it could be conceived that the renal handling
of uric acid differs between patients with and without
kidney disease (or between patients with one solitary
graft-kidney and patients with two normal kidneys),
we compared the renal transplant recipients to the
bone-marrow transplant patients: their values of frac-
tional clearance of uric acid, however, did not differ.
GFR was comparable in both CsA-treated groups
(Table 2a, b). The fractional clearance of uric acid
increases only minimally as long as GFR is above
40 ml/min but increases substantially when GFR falls
below 40 ml/min [17] (see Steele and Rieselbach's
controls in Figures 2 and 3). The GFR of the living
related kidney donors before and at 1 year after
unilateral nephrectomy was higher (P<0.05) than that
of the bone-marrow transplant patients and the renal
transplant patients receiving CsA. As one would expect
from their higher GFR, their fractional clearance of
uric acid was somewhat lower, albeit without statistic-
ally significant difference (Table 2a). The fact, that the
fractional clearance of the bone-marrow transplant
patients before transplantation was significantly higher
than that of the living related kidney donors (P<0.05)
most probably results from their better hydration
(3000 ml of i.v. fluid/24 h) and/or drug interference
(multidrug regimens before transplantation).
To ensure that the fractional clearance of uric acid
of subjects with a healthy, single kidney is comparable
to that of subjects with two moderately diseased, but
not immunosuppressed kidneys and identical GFR, we
compared the results of the fractional clearance of uric
acid of our Jiving related kidney donors with those
obtained in a group of patients with chronically dis-
eased kidneys of variable degree and origin described
by Steele and Rieselbach in 1967 [17] and found no
difference. One can easily see in Figure 2 that there is
an almost perfect agreement of fractional clearance of
uric acid in relation to GFR between Steele's and our
patients. When the results of the fractional clearance
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Fig. 2. Fractional clearance of uric acid in relation to inulin clearance in living related kidney donors and in patients with variable degrees
of renal failure described by Steele and Rieselbach [17].
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Fractional clearance of uric acid in relation to inulin clearance in CsA-treated patients and in patients with variable degTees of renal
described by Steele and Rieselbach [17].
of uric acid of our CsA-treated patients (bone-marrow-
and renal transplant patients) were graphically super-
posed on Steele's results, there was again a very good
agreement (Figure 3). The latter further confirms our
finding that the fractional clearance of uric acid in
CsA-treated patients is not different from the fractional
clearance of uric acid in subjects with comparable renal
function but without CsA.
All reports in the literature describing lower frac-
tional clearance of uric acid in CsA-treated patients as
compared to patients on azathioprine refer to creatin-
ine clearance [3-6]. We therefore also calculated the
fractional clearances of uric acid in relation to creatin-
ine clearance. The results (data not shown) were exactly
congruent in that there were no differences in the
fractional clearance of uric acid between groups. Of
note, our creatinine-based fractional clearances or uric
acid are in the range of 7.3-9.5%, which is in good
agreement with those of other authors [3,13,18].
In conclusion, there is no difference in the fraction-
al clearance of uric acid between patients receiving
CsA and controls without any immunosuppressive
drug. The fractional clearance of uric acid remains
unchanged before, during, and after CsA therapy.
Therefore there is no evidence for impaired tubular
handling of uric acid, induced by a CsA-specific tubulo-
toxic effect. Hyperuricaemia in CsA-treated patients is
simply a consequence of CsA-induced diminished renal
function and is reversible after its withdrawal, if GFR
is restored.
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